Navigation Links
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates
Date:7/22/2013

CARLSBAD, Calif., July 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced data from a Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates.  In this study, patients treated with ISIS-APOCIIIRx experienced reductions of up to 70 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides.  In addition, patients treated with ISIS-APOCIIIRx experienced an up to 52 percent increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles.  Isis is also evaluating ISIS-APOCIIIRx in this Phase 2 study as a monotherapy in patients with severely high triglycerides and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.

The Phase 2 study of ISIS-APOCIII­Rx was a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx.  The portion of the study reported today was conducted in patients with high to severely elevated triglyceride levels (between 225 and 2,000 mg/dL) on stable doses of fibrates. 

Table 1:  ISIS-APOCIIIRx Produced Statistically Significant Reductions of Triglycerides, ApoC-III and ApoC-III Associated VLDL in a Phase 2 Study in Patients With High Triglyceride Levels Treated With Stable Doses of Fibrates.  Mean % Changes From Baseline at Primary Endpoint.Placebo + Fibrate

(n=8)

ISIS-APOCIIIRx 200 mg + Fibrate 

(n=8)

ISIS-APOCIIIRx 300 mg + Fibrate

(n=10)ApoC-III

-2.2%

-59.4% (p<0.0001)


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (Nasdaq: ERES ) announced today that it will ... May 2, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
... April 15, 2011 Atrium Medical Corporation has provided ... Atrium University, at www.AtriumU.com .  "Atrium has been ... for our customers," said Jeff McGill, Senior Vice President ... guidelines for companies, interactions with nurses and physicians, we ...
Cached Medicine Technology:ERT Reports First Quarter 2011 Operating Results on May 2, 2011 2Atrium Provides Grant to Establish Education Web Site at AtriumU.com 2
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... A series of new guidelines for cardiac specialists has ... receive a mechanical heart-pumping device. "The new guidelines ... circulatory support device, and how early in the process ... device," says Jeffrey A. Morgan, M.D., associate director of ...
... 15 (HealthDay News) -- U.S. scientists who completed the ... will improve the ability to diagnose and treat the ... an approach that decodes the 1 to 2 percent ... team, led by researchers at the U.S. National Institutes ...
... Kobe City University of Foreign Studies surveyed and questioned Twitter ... on the social media site two weeks after the Tohoku ... determine what benefits such a system can bring to people ... news. The researchers found that people in directly affected ...
... Meat and poultry sold in the United States is widely ... bacteria that can cause serious illnesses in humans, a new ... to S. aureus range from mild skin infections ... In the new nationwide study, researchers analyzed 136 samples ...
... FRIDAY, April 15 (HealthDay News) -- Teens who start school ... crashes, a new study finds. But starting the school ... reduce impulsiveness, another study finds. In 2008, the weekday ... Va., was about 41 percent higher than for the same ...
... when occurring with hay fever, are nine times more likely ... reveals. The study was conducted by the University ... and Monash University. Published online in the ... reported on evidence from a clinical study of around 1400 ...
Cached Medicine News:Health News:Scientists Spot Key Gene Mutations in Melanoma 2Health News:Twitter and natural disasters 2Health News:Twitter and natural disasters 3Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 2Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 3Health News:Early School Start Tied to More Teen Crashes: Study 2Health News:Childhood eczema and hay fever leads to adult allergic asthma 2
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... Bridge assembly allows internal or ... cooling coil allows rapid cool-down ... within approximately 10 C of ... is only 5.7 inches wideideal ...
Inquire...
Medicine Products: